XML 174 R22.htm IDEA: XBRL DOCUMENT
v3.20.1

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2020
Kite Pharma Inc |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement for the three months ended March 31, 2020 and 2019 were as follows (in thousands):
| Three Months Ended March 31, |  |
| 2020 |  | 2019
Revenue related to Kite agreement: |  |  |
Recognition of license and stand-ready fee | $ | 6,227 |  |  | $ | 6,159 |
Research services | 992 |  |  | 2,153 |
Total | $ | 7,219 |  |  | $ | 8,312 |
Pfizer SB-525 |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement for the three months ended March 31, 2020 and 2019 were as follows (in thousands):
| Three Months Ended March 31, |  |
| 2020 |  | 2019
Revenue related to Pfizer SB-525 agreement: |  |  |
Recognition of upfront fee and research services | $ | 2,190 |  |  | $ | (3,040) |
Milestone achievement | 993 |  |  | — |
Total | $ | 3,183 |  |  | $ | (3,040) |
Pfizer |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement for the three months ended March 31, 2020 and 2019 were as follows (in thousands):
| Three Months Ended March 31, |  |
| 2020 |  | 2019
Recognition of upfront fee related to Pfizer C9ORF72 agreement | $ | 360 |  |  | $ | 615 |
Sanofi |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement for the three months ended March 31, 2020 and 2019 were as follows (in thousands):
| Three Months Ended March 31, |  |
| 2020 |  | 2019
Revenue related to Sanofi agreement: |  |  |
Recognition of upfront fee | $ | (729) |  |  | $ | 752 |
Research services | 1,720 |  |  | 1,197 |
Milestone achievement | (492) |  |  | — |
Total | $ | 499 |  |  | $ | 1,949 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerSB525Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |